Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact The Gross Law Firm about pending Class Action - IOVA

Core Points - The Gross Law Firm has issued a notice to shareholders of Iovance Biotherapeutics, Inc. regarding a class action lawsuit for shareholders who purchased shares during the specified class period [1] - The class period is defined as May 9, 2024, to May 8, 2025, with allegations that Iovance provided misleading statements about its growth potential while concealing material adverse facts [3] - Following the announcement of disappointing financial results and a revenue guidance reduction on July 25, 2024, Iovance's stock price fell dramatically by approximately 44.795% in one day, from $3.17 to $1.75 per share [3] Allegations and Financial Impact - The complaint alleges that Iovance was not equipped to generate demand for its treatments and failed to capitalize on existing demand through its treatment centers [3] - The company attributed its poor financial results and lowered guidance to several factors, including maintenance of its iCTC, lower-than-expected Proleukin sales, and the variable pace of treatment initiation by ATCs [3] - The significant drop in stock price indicates a severe market reaction to the company's financial disclosures and guidance adjustments [3] Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 14, 2025, to participate in potential recovery efforts [4] - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4] - There is no cost or obligation for shareholders to participate in the class action [4]